Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Open Access
- 3 July 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (28), 26483-26493
- https://doi.org/10.18632/oncotarget.4494
Abstract
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancerKeywords
This publication has 38 references indexed in Scilit:
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast CancerCancer Cell, 2012
- Deep Clonal Profiling of Formalin Fixed Paraffin Embedded Clinical SamplesPLOS ONE, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Advancing a clinically relevant perspective of the clonal nature of cancerProceedings of the National Academy of Sciences, 2011
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumorsJCI Insight, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal AdenocarcinomaPLoS Medicine, 2007
- Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysisCytometry, 1996